The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Electrolytes comprising at least one lithium salt and at least two ionic liquids, at least one of which is an ionic liquid resulting from the association of at least one cation complying with the following formula (I): ##STR00001##
In which: R.sup.1 is an acyclic hydrocarbon group; n is an integer ranging from 0 to 3; m is an integer ranging from 1 to 4; and at least one Y anion.

Electrolytes comprising at least one lithium salt and at least two ionic liquids, at least one of which is an ionic liquid resulting from the association of at least one cation complying with the following formula (I): ##STR00001##
In which: R.sup.1 is an acyclic hydrocarbon group; n is an integer ranging from 0 to 3; m is an integer ranging from 1 to 4; and at least one Y anion.

The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present invention provides compounds and methods for the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy.

The present invention provides compounds and methods for the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy.

The present invention discloses compounds of formula (I) that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD). ##STR00001##

The present invention provides a compound having the structure: ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are each independently H, halogen, CF.sub.3 or C.sub.1-C.sub.4 alkyl, wherein two or more of R.sub.1, R.sub.2, R.sub.3, R.sub.4, or R.sub.5 are other than H; R.sub.6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R.sub.1 is CF.sub.3, R.sub.2 is H, R.sub.3 is F, R.sub.4 is H, and R.sub.5 is H, or R.sub.1 is H, R.sub.2 is CF.sub.3, R.sub.3 is H, R.sub.4 is CF.sub.3, and R.sub.5 is H, or R.sub.1 is Cl, R.sub.2 is H, R.sub.3 is H, R.sub.4 is F, and R.sub.5 is H, or R.sub.1 is CF.sub.3, R.sub.2 is H, R.sub.3 is F, R.sub.4 is H, and R.sub.5 is H, or R.sub.1 is CF.sub.3, R.sub.2 is F, R.sub.3 is H, R.sub.4 is H, and R.sub.5 is H, or R.sub.1 is Cl, R.sub.2 is F, R.sub.3 is H, R.sub.4 is H, and R.sub.5 is H, then B is other than ##STR00002##
or a pharmaceutically acceptable salt thereof.